Next-generation flu vaccines
Influenza affects millions of people, with 500 000 casualties annually. Current vaccine effectivity is around 40 %, meaning that 60 % of those vaccinated are not sufficiently protected. The EU-funded INDIGO project involves public and private R&D organisations in the EU, India and United States for the development of two influenza vaccine concepts with the goal to achieve < 10 % instead of 60 % non-responders, lower costs and better accessibility. The first concept combines a low dose of a commercial, inactivated, seasonal flu vaccine with a novel adjuvant, aiming to obtain proof-of-concept in phase I and IIa trials within 5 years. The second concept is based on innovations including a recombinant viral hemagglutinin with increased immunogenicity, a potent adjuvant and needle-free delivery by intradermal patches. The plans are realistic with a high probability to deliver next-generation flu vaccines.
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action
02909 2468 Providence